U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H20N2O3S
Molecular Weight 356.4405
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIOGLITAZONE

SMILES

CCc1ccc(CCOc2ccc(cc2)CC3C(=NC(=O)S3)O)nc1

InChI

InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)

HIDE SMILES / InChI

Molecular Formula C19H20N2O3S
Molecular Weight 356.4405
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including http://reference.medscape.com/drug/actos-pioglitazone-342726 | https://www.drugbank.ca/drugs/DB01132 | https://www.drugs.com/cdi/pioglitazone.html | https://www.ncbi.nlm.nih.gov/pubmed/25760794

Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione class with hypoglycemic action used in the treatment of type 2 diabetes. Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces the quantity of glucose and glycated hemoglobin in the bloodstream. Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin. Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of components of its pharmaceutical forms. It is ineffective and possibly harmful to diabetes mellitus type 1 and diabetic ketoacidosis. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems.

Originator

Curator's Comment:: # Takeda Chemical Industries, Ltd

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

9.3199683E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
890 ng/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8662 ng × h/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.6 h
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.75 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources: Page: p.7, 9
unhealthy, 5-12
n = 18
Health Status: unhealthy
Condition: Autistic disorder|Asperger syndrome
Age Group: 5-12
Sex: M+F
Population Size: 18
Sources: Page: p.7, 9
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Disc. AE: Edema, ALT increased...
AEs leading to
discontinuation/dose reduction:
Edema (mild, 1.67%)
ALT increased (grade 2-4, 1.67%)
Sources: Page: p.983, 984
180 mg 1 times / day multiple, oral
Overdose
Dose: 180 mg, 1 times / day
Route: oral
Route: multiple
Dose: 180 mg, 1 times / day
Sources: Page: p.21
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.21
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Disc. AE: Congestive heart failure, Edema...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Edema
Hepatic failure (grade 5)
Fractures
Bladder cancer
Hypoglycemia
Macular edema
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
ALT increased grade 2-4, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Edema mild, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Bladder cancer Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Congestive heart failure Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Fractures Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hypoglycemia Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Macular edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hepatic failure grade 5
Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells.
2006
Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells.
2006 Apr
Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.
2006 Aug
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
2006 Aug 29
Rosiglitazone inhibits mouse liver regeneration.
2006 Dec
In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway.
2006 Dec 15
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
2006 Jan 10
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
2006 Jul
Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.
2006 Jul
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.
2006 Jul
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
2006 Jun
Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
2006 Mar-Apr
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
2006 May
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
2006 Nov 7
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells.
2006 Oct
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
2006 Oct
Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma.
2006 Oct 15
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin].
2006 Sep
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
2007
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
2007 Apr
Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma.
2007 Feb
Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice.
2007 Jan
Effect of pioglitazone treatment on behavioral symptoms in autistic children.
2007 Jan 5
[Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells].
2007 Jul
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
2007 Jul
Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
2007 Mar
Troglitazone and pioglitazone interactions via PPAR-gamma-independent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines.
2007 Mar
Ligands of peroxisome proliferator-activated receptor inhibit homocysteine-induced DNA methylation of inducible nitric oxide synthase gene.
2007 May
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
2007 Sep 12
MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone.
2007 Sep 4
Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
2008 Apr
Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
2008 Feb
Treating Hispanic patients for type 2 diabetes mellitus: special considerations.
2008 May
JNK- and IkappaB-dependent pathways regulate MCP-1 but not adiponectin release from artificially hypertrophied 3T3-L1 adipocytes preloaded with palmitate in vitro.
2008 May
Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.
2008 Oct
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
2008 Sep
Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.
2009
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
2009 Apr
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
2009 Aug
Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.
2009 Jan
Retinol saturase promotes adipogenesis and is downregulated in obesity.
2009 Jan 27
Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.
2009 Mar
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009 May
Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
2009 Oct 30
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma.
2010 Apr
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
2010 Apr 15
Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.
2010 Feb
Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene.
2010 Jun
Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.
2010 Oct 6
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
2010 Sep 25
Patents

Sample Use Guides

Initiate ACTOS (Pioglitazone) at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily.
Route of Administration: Oral
For the cell counting assay, Human aortic smooth muscle cells (HASMCs) were seeded at 3× 10^3 cells on to a 96-well dish; 24 hours after the plating, the cells were serum-starved to render them quiescent by replacing the medium with DMEM containing 0.2% FBS. The quiescent SMCs were then preincubated with globular adiponectin (1μg/mL or 3μg/mL) or pioglitazone (1μM or 10μM) for 30min. PDGF-BB (10ng/mL) was added to stimulate the cells for 24hours. These cells were incubated with 10 μl of CCK (cell counting kit)-8 (DOJINDO) or WST-1 (Roche) solution for 2hours before conducting the measurements. We measured the absorbance at 450nm using a microplate reader. 10 μl of BrdU (Roche) solution was added these cells simultaneously with PDGF-BB. BrdU incorporation was measured by chemiluminescent assay
Substance Class Chemical
Created
by admin
on Sat Jun 26 11:28:17 UTC 2021
Edited
by admin
on Sat Jun 26 11:28:17 UTC 2021
Record UNII
X4OV71U42S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIOGLITAZONE
EMA EPAR   HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PIOGLITAZONE [WHO-DD]
Common Name English
5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
PIOGLITAZONE [MI]
Common Name English
PIOGLITAZONE [INN]
Common Name English
ZACTOS
Brand Name English
5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
AD-4833
Code English
PIOGLITAZONE [EMA EPAR]
Common Name English
PIOGLITAZONE [VANDF]
Common Name English
(RS)-5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, (+/-)-
Systematic Name English
PIOGLITAZONE [HSDB]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-
Systematic Name English
PIOGLITAZONE [IARC]
Common Name English
GLUSTIN
Brand Name English
U-72107
Code English
(+/-)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Common Name English
5-(4-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000170118
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-VATC QA10BD09
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
FDA ORPHAN DRUG 583017
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000170119
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
LIVERTOX 780
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-ATC A10BD05
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-VATC QA10BD06
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000180186
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
EU-Orphan Drug EU/3/14/1245
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NCI_THESAURUS C98241
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000170118
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000175374
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000170119
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-ATC A10BD12
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000011272
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000011272
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-ATC A10BD09
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000180190
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-ATC A10BG03
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-VATC QA10BG03
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000011272
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-VATC QA10BD05
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-ATC A10BD06
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
WHO-VATC QA10BD12
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
NDF-RT N0000175596
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
Code System Code Type Description
DRUG CENTRAL
2179
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
NCI_THESAURUS
C71633
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
MERCK INDEX
M8835
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY Merck Index
PUBCHEM
4829
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
CAS
111025-46-8
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
INN
6343
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
CAS
105355-27-9
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
SUPERSEDED
ChEMBL
CHEMBL595
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
WIKIPEDIA
PIOGLITAZONE
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
EPA CompTox
111025-46-8
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
EVMPD
SUB09857MIG
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
IUPHAR
2694
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
FDA UNII
X4OV71U42S
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
RXCUI
33738
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY RxNorm
HSDB
7322
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
CAS
198077-89-3
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
SUPERSEDED
LACTMED
Pioglitazone
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
DRUG BANK
DB01132
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
MESH
C060836
Created by admin on Sat Jun 26 11:28:18 UTC 2021 , Edited by admin on Sat Jun 26 11:28:18 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
IC50
TARGET -> AGONIST
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC